Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    • News

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments

  • In News
  • December 4, 2023
  • Alinda Gupta
Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments

Precision microbiome company Microba (ASX: MAP) and the US-based F&B company International Flavors & Fragrances (IFF) have entered the second phase of their joint research initiative, aiming to develop novel microbiome-based treatments for various allergies. The collaboration, a strategic move within the bioscience and health sectors, signals a step forward in addressing the need for novel solutions in allergy treatment.

This is crucial in Australia, which has one of the highest rates of allergies globally. Recently, the Government set aside funding of $16.6 million from 2022-23 to 2025-26 so that the Australasian Society of Clinical Immunology and Allergy (ASCIA) and Allergy & Anaphylaxis Australia (A&AA) can set up a National Allergy Council. This further underscores the importance of Microba and IFF’s mission.

Under the terms of the research agreement, IFF is set to pay Microba approximately $924,150, with the possibility of additional stages leading to licensing agreements and royalties. The financial commitment reflects IFF’s interest in leveraging Microba’s expertise in precision microbiome science to advance allergy solutions.

Microba’s Chief Executive Officer, Dr Luke Reid, said, “We are excited to continue our partnership with IFF with a view to creating efficacious treatments for allergy sufferers. This program strongly aligns with Microba’s mission of improving human health, and we are delighted to partner with IFF as a leader in the field to achieve this goal.”

Microba focuses on chronic disease therapeutics and global gut microbiome testing. In Q1 FY24, it reported strong Q1 FY24 results with a 62% YoY revenue increase in domestic Personal Testing and a 72% growth internationally. The uptake of its healthcare test for gut health, MetaXplore, surged by 33% in Australia between June and September. It reported a cash burn of over $5.2 million against customer receipts of $1.7 million. By quarter-end, Microba had $25.9 million in cash reserves.

The ongoing research collaboration with IFF revolves around a discovery program to isolate key species identified for allergy treatment. This marks the second agreement between Microba and IFF, with the initial research collaboration commencing in November 2021. 

In the initial stage, Microba identified lead species, and IFF made selections for advancement. The current phase signifies the progression of selected Project Species from the first stage to the second. The overarching goal of the second stage is the successful isolation of strains from the Selected Project Species for IFF and the characterisation of those strains.

The agreement grants IFF an exclusive option to license these strains for development and commercialisation. The research initiative commenced on December 4, 2023, and is expected to conclude upon the delivery of the final report by Microba to IFF around October 2024.

As the collaboration enters this critical second stage, shareholders have their eyes peeled for potential breakthroughs.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • asx map
  • IFF
  • International Flavors and Fragrances
  • Luke Reid
  • microba
  • microbiome
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.